Deana Mohr and Jenny Prange win Female Innovator of the Year Award
MUVON's co-founders Deana Mohr and Jenny Prange received the Female Innovator of the year Award at the 6th Female Innovation Forum. A...
Deana Mohr and Jenny Prange win Female Innovator of the Year Award
MUVON's CEO & CTO nominated for Female Innovator of the Year Award
MUVON enters TOP 100 SWISS STARTUPS list as a top 3 Biotech
MUVON Therapeutics AG among the TOP 3 Swiss biotech leaders according to public voting
MUVON finishes as Top 3 finalist for the ZKB Pionierpreis 2023 with our tissue engineering therapy
First in Human trial results published, demonstrating safety and feasibility of MUVON's SUI Therapy
MUVON Therapeutics nominated as finalist for 2023 ZKB Pionierpreis
The leadership from MUVON Therapeutics AG will be attending JP Morgan Healthcare week in Jan 2023
MUVON Therapeutics announces appointments to its Board of Directors and Scientific Advisory Board
Muvon Therapeutics Announces First Patient Enrolled in Phase II Clinical Study
CEO Deana Mohr honored to present MUVON to Prof. Shinya Yamanaka, godfather of iPSCs
Muvon Therapeutics Announces Successful Phase I Clinical Study in Female Patients with SUI
Joint statement by the leading patient group WFIPP and MUVON Therapeutics AG
MUVON Therapeutics is supported by the Lichtsteiner Foundation
MUVON's CEO Deana Mohr featured in Top 30 In Vivo's Rising Leaders 2022
CEO Deana Mohr presented MUVON in interview for BioInnovation Spotlight
Translation and automation hurdles for cell therapies
MUVON wins second place at IFAS Innovation Challenge 2021
Deana Mohr wins spot in Venture Leaders Medtech 2021
MUVON featured by Startupticker